Nathan Reticker-Flynn

Nathan Reticker-Flynn is a tumor immunologist and Biomedical Engineer working at the interfaces of cancer metastasis, tumor evolution, adaptive immunity, and immunotherapy. He received his PhD from the Massachusetts Institute of Technology while working with Dr. Sangeeta Bhatia as part of the Harvard-MIT Division of Health Sciences and Technology. His doctoral studies focused upon developing screening platforms for interrogating interactions between tumors and extracellular matrix during metastatic progression and led to the discovery of aberrant glycosylation motifs that promote metastasis. Dr. Reticker-Flynn performed his postdoctoral studies in the laboratory of Dr. Edgar Engleman at Stanford University School of Medicine. There, his work has focused on using systems approaches and mouse models to investigate tumor-immune interactions during metastasis and responses to immunotherapies. His discoveries include the revelation that effective immunotherapies require systemic activation of anti-tumor immunity and that lymph node metastases serve to reeducate adaptive immune responses in a manner that promotes distant metastasis. Dr. Reticker-Flynn is currently an Assistant Professor at Stanford University in the Department of Otolaryngology and a member of the Stanford Cancer Institute. His lab uses systems approaches, combining patient samples and mouse models, to elucidate the mechanisms of tumor-immune tolerance during metastatic progression and develops novel immunotherapies that reverse tumor-specific tolerance to treat patients with metastatic disease.